Children and Adolescent Exposures to Atomoxetine Hydrochloride Reported to a Poison Control Center
Authors:
Sasko D. Stojanovski a;
Renee F. Robinson b;
S David Baker c;
Marcel J. Casavant d;
John R. Hayes e;
Milap C. Nahata f
| Affiliations: | a College of Pharmacy, Ohio State University and Children's Research Institute, Columbus, OH, USA |
| b College of Medicine and Pharmacy, Ohio State University and Children's Hospital, Columbus, OH, USA | |
| c Central Ohio Poison Center, Children's Hospital, Columbus, OH, USA | |
| d Colleges of Pharmacy, Medicine and Public Health, Ohio State University and Central Ohio Poison Center, Children's Research Institute, Columbus, OH, USA | |
| e Children Research Institute, Columbus, OH, USA | |
| f Colleges of Pharmacy and Medicine, Ohio State University, Children's Hospital and Children's Research Institute, Columbus, OH, USA |
DOI:
10.1080/15563650600584311
Publication Frequency:
10 issues per year
Subject:
Clinical Toxicology;
Formats available:
HTML
(English)
:
PDF
(English)
Previously published as:
Journal of Toxicology: Clinical Toxicology
(0731-3810)
until 2005
View Article:
View Article (PDF)
View Article (HTML)
Abstract
Background. Atomoxetine hydrochloride, a selective norepinephrine reuptake inhibitor was FDA approved for patients with attention-deficit/hyperactivity disorder. Little is known about adverse drug reactions of atomoxetine following an overdose among children. The objective of our study was to evaluate the type of atomoxetine adverse drug reactions in relation to dose. Methods. We evaluated children exposed to atomoxetine reported to a poison center from January-December 2004. Results. Sixty-four cases met all inclusion criteria. Twenty-one patients had an adverse drug reaction (15 at dosage range 0.52-6.25 mg/kg): agitation, headache, erythema, rash, elevated blood pressure and heart rate, nausea, emesis, and lethargy. In 51 patients, weights were known: group 1 (n = 43) received higher than maximum recommended doses >1.4 mg/kg and group 2 (n = 8) received ≤1.4 mg/kg. There were no differences in adverse drug reactions in group 1 versus 2. Eight patients were admitted to a healthcare facility and all were discharged without any sequelae. Hypertension occurred in 3 of 9 patients for whom blood pressure was recorded. Conclusion. At the doses reported, adverse drug reactions did not correlate with atomoxetine dose. Hypertension may occur in some patients following atomoxetine overdose.
|
| Keywords: Strattera®; Atomoxetine hydrochloride; Overdose exposures; Pediatrics |
| view references (16) : view citations |


Download Citation
CiteULike
Del.icio.us
BibSonomy
Connotea